{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T18:54:01Z","timestamp":1787079241065,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.metabol.2014.09.008","type":"journal-article","created":{"date-parts":[[2014,9,28]],"date-time":"2014-09-28T11:34:28Z","timestamp":1411904068000},"page":"482-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Risk of diabetes in patients treated with HMG-CoA reductase inhibitors"],"prefix":"10.1016","volume":"64","author":[{"given":"Yongin","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EunYeong","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younjeong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujung","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Woo","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Soo","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Seok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2014.09.008_bb0005","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/j.amjcard.2012.04.002","article-title":"Management of cardiovascular risk: the importance of meeting lipid targets","volume":"110","author":"Gotto","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2014.09.008_bb0010","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2014.09.008_bb0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-200464002-00005","volume":"64","author":"Sever","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2014.09.008_bb0020","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2014.09.008_bb0025","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2014.09.008_bb0030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2014.09.008_bb0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","author":"Freeman","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2014.09.008_bb0040","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.amjcard.2012.12.037","article-title":"Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus","volume":"111","author":"Navarese","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2014.09.008_bb0045","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2014.09.008_bb0050","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2125.2012.04403.x","article-title":"Statins and risk of treated incident diabetes in a primary care population","volume":"75","author":"Zaharan","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2014.09.008_bb0055","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5124\/jkma.2010.53.7.544","article-title":"Drug Utilization Review (DUR) policy of government and directivity","volume":"53","author":"Yoon","year":"2010","journal-title":"J Korean Med Assoc"},{"key":"10.1016\/j.metabol.2014.09.008_bb0060","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/bmj.330.7497.960","article-title":"Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding","volume":"330","author":"Mamdani","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2014.09.008_bb0065","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.metabol.2014.09.008_bb0070","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2014.09.008_bb0075","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3949\/ccjm.79a.12091","article-title":"Statins and diabetes risk: fact, fiction, and clinical implications","volume":"79","author":"Rocco","year":"2012","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.metabol.2014.09.008_bb0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","article-title":"Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative","volume":"172","author":"Culver","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.metabol.2014.09.008_bb0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/157488609789006949","article-title":"Adverse effects of statins\u2014mechanisms and consequences","volume":"4","author":"Be\u0142towski","year":"2009","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.metabol.2014.09.008_bb0090","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.metabol.2014.02.014","article-title":"Statin treatment and new-onset diabetes: a review of proposed mechanisms","volume":"63","author":"Brault","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2014.09.008_bb0095","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/en.2008-0161","article-title":"Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic \u03b2-cells","volume":"149","author":"Xia","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2014.09.008_bb0100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mce.2008.05.015","article-title":"Mitochondrial dysfunction in pancreatic \u03b2-cells in type 2 diabetes","volume":"297","author":"Mulder","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.metabol.2014.09.008_bb0105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.freeradbiomed.2011.10.449","article-title":"Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes","volume":"52","author":"Kwak","year":"2011","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.metabol.2014.09.008_bb0110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.tem.2012.06.004","article-title":"Mitochondrial dysfunction in white adipose tissue","volume":"23","author":"Kusminski","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.metabol.2014.09.008_bb0115","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00125-006-0269-5","article-title":"Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control","volume":"49","author":"Nakata","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2014.09.008_bb0120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/1474651411413644","article-title":"Sarcopenia and diabetes: pathogenesis and consequences","volume":"11","author":"Khamseh","year":"2011","journal-title":"Br J Diabetes Vasc Dis"},{"key":"10.1016\/j.metabol.2014.09.008_bb0125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.metabol.2014.09.008_bb0130","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archinternmed.2012.2171","article-title":"Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial","volume":"172","author":"Golomb","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.metabol.2014.09.008_bb0135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/FPC.0b013e32834a5585","article-title":"The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action","volume":"21","author":"Hafner","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.metabol.2014.09.008_bb0140","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1055\/s-0031-1299961","article-title":"Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyllutaryl coenzyme A reductase","volume":"52","author":"Fujino","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.metabol.2014.09.008_bb0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1254\/jphs.10241FP","article-title":"Pitavastatin increases ABCA1 expression by dual mechanisms: SREBP2-driven transcriptional activation and PPAR\u03b1-dependent protein stabilization but without activating LXR in rat hepatoma McARH7777 cells","volume":"116","author":"Maejima","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.metabol.2014.09.008_bb0150","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.bbrc.2004.09.122","article-title":"Effect of pitavastatin on apolipoprotein AI production in HepG2 cell","volume":"324","author":"Maejima","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2014.09.008_bb0155","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5551\/jat.12.163","article-title":"Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes","volume":"12 (Suppl. 1)","author":"Saiki","year":"2005","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.metabol.2014.09.008_bb0160","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1475-2840-12-S1-S2","article-title":"Pitavastatin in cardiometabolic disease: therapeutic profile","volume":"12","author":"Masana","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2014.09.008_bb0165","series-title":"Pitavastatin is without effect on glycaemic parameters in metabolic syndrome (CAPITAIN Study)","author":"Hounslow","year":"2012"},{"key":"10.1016\/j.metabol.2014.09.008_bb0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jdi.12032","article-title":"Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia","volume":"4","author":"Mita","year":"2013","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.metabol.2014.09.008_bb0175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5551\/jat.E562","article-title":"Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus","volume":"15","author":"Yamakawa","year":"2008","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.metabol.2014.09.008_bb0180","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2014.09.008_bb0185","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2337\/dc05-2465","article-title":"Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study","volume":"29","author":"Shepherd","year":"2006","journal-title":"Diabetes Care"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604951400290X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604951400290X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:05:54Z","timestamp":1758427554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002604951400290X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S002604951400290X"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2014.09.008","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of diabetes in patients treated with HMG-CoA reductase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2014.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}